Weekly Marketing Briefing: Cosentyx

Week ending August 30, 2026

1. How AI is currently framing the brand

AI answers frame Cosentyx in a predominantly neutral, clinical, and comparison-oriented way. The recurring positioning is that Cosentyx is an IL-17A inhibitor, with differentiation explained through mechanism, dosing, treatment fit, and safety rather than a clear efficacy hierarchy. Answers frequently use shared-decision language—“both are good options” and “the best choice depends on the patient”—and remain highly cautious: hedging/disclaimer language appeared 98 times, while infection-risk language appeared 75 times. This week’s brand answers also became slightly less assertive overall, with overclaim-language hits declining to 29 from 33.

2. Share of voice vs. named competitors

Competitor references remain prominent inside answers about Cosentyx:

• Humira: 15 mentions, down from 18
• Stelara: 14, down from 16
• Enbrel: 14, down from 17
• Taltz: 14, down from 16
• Remicade: 6, up from 4
• Skyrizi: 4, unchanged
• Tremfya: 2, down from 3
• Bimzelx: 1, up from 0

No major competitor is gaining substantial ground this week, although Remicade and Bimzelx increased from low bases. The most competitor-heavy prompts are explicit comparison questions: Cosentyx versus Humira for plaque psoriasis, Stelara for practical differences, Enbrel for whether Cosentyx is “stronger,” and Taltz for nurse-facing treatment discussions. Competitors also appear in broader PsA differentiation, switching, and dosing-convenience answers.

3. Messaging consistency and content gaps

The largest gap is not awareness but precision and consistency. AI reliably repeats that Cosentyx targets IL-17A, but often gives generic differentiation: “different target,” “different dosing,” and “individual response varies.” A stronger, evidence-linked PsA and psoriasis comparison hub could explain mechanism, approved-indication context, dosing, treatment goals, and appropriate comparison boundaries without defaulting to competitor-led framing.

Dosing content needs urgent clarification. Answers generally describe weekly loading followed by every-four-week maintenance, but the reported maintenance start varies between Week 5 and Week 8. This is a clear opportunity for indication-specific, device-specific dosing pages and visual schedules.

The generic/biosimilar question is another priority. Several answers correctly distinguish biologics from traditional generics, but some broadly suggest Cosentyx is “often available through biosimilar products.” A definitive, regularly updated substitution/access explainer could reduce confusion and protect branded search real estate.

Safety and PI content also show inconsistency: answers conflict on whether Cosentyx has a boxed warning, and monitoring language sometimes presents TB screening or routine labs as universally “required.” A label-controlled safety center should clearly separate contraindications, warnings, baseline evaluation, ongoing monitoring, vaccines, pregnancy/lactation, and IBD considerations.

4. Overclaim / compliance-adjacent language watch

Reviewers should be aware that AI-generated answers currently circulate language such as “best,” “stronger,” “superior,” “most effective,” “leading,” and “strongest.” These appeared 29 times this week, including in answers discussing Cosentyx versus Taltz, Enbrel, and Humira. Most responses ultimately reject a simple superiority ranking, but the terms remain part of the generated conversational environment and warrant monitoring.

5. Recommended actions

1. Commission an indication-specific Cosentyx dosing and administration hub. Resolve the Week 5/Week 8 inconsistency with approved, visual schedules and separate pages for pen, syringe, and infusion use.
2. Build a “Cosentyx vs. other biologics” evidence explainer targeting Humira, Stelara, Enbrel, and Taltz queries; emphasize mechanism, indication, dosing, safety considerations, and treatment fit.
3. Publish a generic vs. biosimilar/substitution FAQ with current market and jurisdiction caveats, since AI is currently blurring these concepts.
4. Create a label-aligned safety and monitoring center addressing boxed-warning status, infection/TB screening, IBD, vaccines, pregnancy, and contraindications.
5. Prioritize consistency testing next week: total inconsistency flags rose to 29 from 26, despite responses falling by 20.